Howard M. Sandler, MD, MS, FASTRO | Authors


Significance of a Phase III Study on Docetaxel With Hormonal & Radiation Therapy in Prostate Cancer

July 15, 2015

Howard M. Sandler, MD, MS, FASTRO, Chair, Radiation Oncology, Ronald H. Bloom Family Chair, Cancer Therapeutics, Cedars Sinai, discusses the significance of a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.